ArticleFrontiers in immunology2022

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.

Fucun Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.